studies

1100A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Andrew M. Hill - Consulting: Janssen
David R. Nelson - Advisory Committees or Review Panels: Merck; Grant/Research
Support: Abbot, BMS, Beohringer Ingelheim, Gilead, Genentech, Merck, Bayer,
Idenix, Vertex, Jansen
Michael W. Fried - Consulting: Merck, Abbvie, Janssen, Bristol Myers Squibb,
Gilead; Grant/Research Support: Merck, AbbVie, Janssen, Bristol Myers Squibb,
Gilead; Patent Held/Filed: HCCPlex
The following authors have nothing to disclose: Teri Roberts, Valerianna Amorosa,
Kamron Pourmand, Gail Matthews, Graham Cooke, Harun Khan, Janice
Main, Ashley Brown, Joy A. Peter, Jennifer Cohn, Camilla S. Graham
FRY graph
1827
Comparative analysis of online patient education
resources relating to Hepatitis C
Rishabh Gulati, Mohammad Nawaz, Sowjanya Kanna, Nikolaos
Pyrsopoulos; Medicine, Rutgers New Jersey Medical School, Newark,
NJ
Introduction: Role of the Internet is ever-increasing in the present
era as the first source of medical information. Imprecise,
partial comprehension of textual information limits its efficacy
in communicating the disease process to the patient. Here, we
report a comparative analysis of readability of patient-centered
text pertaining to Hepatitis C available online. Methods: In
March 2015, patient-centered information from websites of
American College of Gastroenterology (ACG), Centers for Disease
Control & Prevention (CDC), American Liver Foundation
(ALF), Mayo Clinic, National Institutes of Health (NIH), Uptodate,
HCVAdvocate & WebMD was downloaded & processed
in Microsoft Word. All data were formatted & categorized
into subsections. Proper nouns, copyright information & certain
medical terms were omitted to limit bias. Text was then analyzed
for their specific level of readability using 7 quantitative
scales: Flesch Reading Ease, Flesch–Kincaid level, Gunning fog
index, SMOG, Coleman-Liau, FRY & New Dale–Chall using
Readability Studio software. Results: Modified documents had
a mean grade level that was 1 less than their original counterparts.
ACG had the highest mean grade level of readability
of it’s content (13.4±0.61), with the lowest being for WebMD
(8.4±0.40). When compared with all subsets, the treatment
subsection had the highest mean grade level (12.2±0.85).
ANOVA analysis showed that there were significant differences
in the grade level depending on the source website (p <
0.05), however there was no significant impact by subsection
when compared with all readability tests. Post hoc Turkey HSD
Analysis showed ACG was written at a significantly higher
grade level than other websites. The treatment section was usually
the most difficult section written when compared with other
subsections (p < 0.05). Conclusion: Patient material is above
the recommended 6 th grade level across all websites. Treatment
section is often the most difficult section to comprehend.
Greater emphasis on clear & simple language is warranted to
increase quality & comprehension of online patient education
resources.
Disclosures:
Nikolaos Pyrsopoulos - Advisory Committees or Review Panels: GILEAD, BMS,
ABBVIE, VITAL THERAPIES, Quest; Grant/Research Support: ABBVIE
The following authors have nothing to disclose: Rishabh Gulati, Mohammad
Nawaz, Sowjanya Kanna
1828
Benefits of Antiviral Treatment and Predictors of Subsequent
Hepatocellular Carcinoma Risk in Chronic Hepatitis
C Patients with or without Sustained Virological
Response to Peg-interferon plus Ribavirin Therapy
Mei-Hsuan Lee 1 , Sheng-Nan Lu 2 , Ming-Lung Yu 3 , Cheng-Yuan
Peng 4 , I-Shyan Sheen 5 , Chen-Hua Liu 6 , Jia-Horng Kao 6 , Wan-Long
Chuang 3 , Hwai-I Yang 7 , Gilbert L’Italien 8 , Yong Yuan 9 , Chien-Jen
Chen 7 ; 1 National Yang-Ming University, Institute of Clinical Medicine,
Taipei, Taiwan; 2 Division of Hepatogastroenterology, Department
of Internal Medicine, Kaohsiung Chang-Gung Memorial
Hospital and Chang Gung University College of Medicine, Kaohsiung,
Taiwan; 3 Hepatobiliary Division, Department of Internal Medicine
and Hepatitis Center, Kaohsiung Medical University Hospital
and Kaohsiung Medical University college of Medicine, Kaohsiung,
Taiwan; 4 Division of Hepatogastroenterology, Department of
Internal Medicine, China Medical University Hospital, Taichung,
Taiwan; 5 Division of Hepatology, Department of Gastroenterology
and Hepatology, Linkou Medical Center, Chang Gung Memorial
Hospital, Tao-Yuan, Taiwan; 6 Graduate Institute of Clinical Medicine,
Department of Internal Medicine and Hepatitis Research Center,
National Taiwan University College of Medicine and Hospital,
Taipei, Taiwan; 7 Genomics Research Center, Academia Sinica,
Taipei, Taiwan; 8 Yale University School of Medicine, New Haven,
CT; 9 Global Health Economics and Outcome Research, Bristol-Myers
Squibb, Princeton, NJ
Background & Aims: The aims of this large follow-up study
were to evaluate the antiviral treatment efficacy in chronic hepatitis
C patients by two distinctive cohorts, and to investigate
the predictability of post-treatment seromarkers for HCC risk
stratified by patients with sustained virological response (SVR)
and non-SVR to antiviral treatment. Methods: The treatment
cohort included 3,133 chronic hepatitis C patients treated with
peg-interferon plus ribavirin (PR) for 6-12 months. In addition,
the untreated cohort consisted of 1,366 anti-HCV seropositives
who participated in a community-based liver cancer screening.
All of them were seronegative for HBsAg and free of HCC
at study entry. The treated patients were followed from the
date starting PR therapy whereas the untreated patients were
followed from the date of enrollment. Both cohorts were followed
to the date of HCC diagnosis, death, or the end of
2012, whichever came first. The Cox’s proportional hazards
model was utilized to estimate the adjusted hazard ratio (HR)
and 95% confidence interval (CI) associated with HCC by
comparing patients with or without antiviral treatment. Among